** Shares of drugmaker ImmunityBio IBRX.O rise 11.1% to $2.3

** Co posts Q1 revenue of $16.5 million, beating analysts' average estimate of $16.02 million, according to data compiled by LSEG

** IBRX reports Q1 net loss of 15 cents/share vs analysts' est of 13 cents/share

** Including session's moves, IBRX stock down 10.7% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))